Department of Pharmacology, University of California, Davis, CA 95616, USA.
Mol Pharmacol. 2011 Jun;79(6):899-909. doi: 10.1124/mol.110.069807. Epub 2011 Mar 1.
Acting as a negative gating modulator, (R)-N-(benzimidazol-2-yl)-1,2,3,4-tetrahydro-1-naphthylamine (NS8593) shifts the apparent Ca(2+)-dependence of the small-conductance Ca(2+)-activated K(+) channels K(Ca)2.1-2.3 to higher Ca(2+) concentrations. Similar to the positive K(Ca) channel-gating modulators 1-ethyl-2-benzimidazolinone (1-EBIO) and cyclohexyl-[2-(3,5-dimethyl-pyrazol-1-yl)-6-methylpyrimidin-4-yl]-amine (CyPPA), the binding site for NS8593 has been assumed to be located in the C-terminal region, in which these channels interact with their Ca(2+) sensor calmodulin. However, by using a progressive chimeric approach, we were able to localize the site-of-action of NS8593 to the K(Ca)2 pore. For example, when we transferred the C terminus from the NS8593-insensitive intermediate-conductance K(Ca)3.1 channel to K(Ca)2.3, the chimeric channel remained as sensitive to NS8593 as wild-type K(Ca)2.3. In contrast, when we transferred the K(Ca)2.3 pore to K(Ca)3.1, the channel became sensitive to NS8593. Using site-directed mutagenesis, we subsequently identified two specific residues in the inner vestibule of K(Ca)2.3 (Ser507 and Ala532) that determined the effect of NS8593. Mutation of these residues to the corresponding residues in K(Ca)3.1 (Thr250 and Val275) made K(Ca)2.3 insensitive to NS8593, whereas introduction of serine and alanine into K(Ca)3.1 was sufficient to render this channel highly sensitive to NS8593. It is noteworthy that the same two residue positions have been found previously to mediate sensitivity of K(Ca)3.1 to clotrimazole and 1-[(2-chlorophenyl)diphenylmethyl]-1H-pyrazole (TRAM-34). The location of Ser507 in the pore-loop near the selectivity filter and Ala532 in an adjacent position in S6 are within the region predicted to contain the K(Ca)2 channel gate. Hence, we propose that NS8593-mediated gating modulation occurs via interaction with gating structures at a position deep within the inner pore vestibule.
作为一种负门控调制剂,(R)-N-(苯并咪唑-2-基)-1,2,3,4-四氢-1-萘基胺(NS8593)将小电导钙激活钾(K(Ca))通道 K(Ca)2.1-2.3 的表观 Ca(2+)依赖性转移到更高的 Ca(2+)浓度。类似于正 K(Ca) 通道门控调节剂 1-乙基-2-苯并咪唑啉酮(1-EBIO)和环己基-[2-(3,5-二甲基吡唑-1-基)-6-甲基嘧啶-4-基]-胺(CyPPA),NS8593 的结合位点被假定位于 C 端区域,在该区域中,这些通道与它们的 Ca(2+)传感器钙调蛋白相互作用。然而,通过使用渐进嵌合方法,我们能够将 NS8593 的作用部位定位到 K(Ca)2 孔。例如,当我们将来自 NS8593 不敏感的中间电导 K(Ca)3.1 通道的 C 末端转移到 K(Ca)2.3 时,嵌合通道对 NS8593 的敏感性与野生型 K(Ca)2.3 相同。相比之下,当我们将 K(Ca)2.3 孔转移到 K(Ca)3.1 时,通道对 NS8593 变得敏感。通过定点突变,我们随后确定了 K(Ca)2.3 内孔前庭中的两个特定残基(Ser507 和 Ala532),它们决定了 NS8593 的作用。将这些残基突变为 K(Ca)3.1 中的相应残基(Thr250 和 Val275)使 K(Ca)2.3 对 NS8593 不敏感,而将丝氨酸和丙氨酸引入 K(Ca)3.1 足以使该通道对 NS8593 高度敏感。值得注意的是,先前已经发现相同的两个残基位置介导了 K(Ca)3.1 对克霉唑和 1-[(2-氯苯基)二苯基甲基]-1H-吡唑(TRAM-34)的敏感性。Ser507 在靠近选择性过滤器的孔环中的位置和 Ala532 在 S6 中的相邻位置都位于预测包含 K(Ca)2 通道门的区域内。因此,我们提出 NS8593 介导的门控调节是通过与内孔前庭深处的门控结构相互作用发生的。
Nat Commun. 2025-4-17
J Neurosci Res. 2023-11
Curr Neuropharmacol. 2023
Cancers (Basel). 2022-10-1
J Comp Physiol A Neuroethol Sens Neural Behav Physiol. 2021-1
Annu Rev Pharmacol Toxicol. 2019-7-23
J Biol Chem. 2010-6-18
Prog Neurobiol. 2010-3-30
Neurosci Lett. 2009-9-3
Bioorg Med Chem Lett. 2008-10-15